Table 2. Genotyping frequencies and the association of genotype with disease progression during ADT.

Gene	Genotype	No. of patients	No. of events	Median (months)	P *	q	HR (95% CI)	P †
Polymorphism
AR	<21	136	81	26	0.023	0.437	1.00
CAG repeats	21	91	65	28			1.07 (0.76–1.51)	0.683
	22–23	165	111	23			0.92 (0.68–1.24)	0.589
	>23	198	149	19			1.11 (0.84–1.47)	0.472
	P-trend						1.02 (0.93–1.12)	0.620

Abbreviations: ADT, androgen-deprivation therapy; HR, hazard ratio; 95% CI, 95% confidence interval; PSA, prostate-specific antigen.

^* P values were calculated using the log-rank test.

^†HRs were adjusted for age, clinical stage, Gleason score, PSA at ADT initiation, PSA nadir, time to PSA nadir, and treatment modality.

P≤0.05 are in boldface.